Clinical Research Centre

CRC

The Mahkota Clinical Research Centre (CRC) was set up to conduct quality and ethical clinical trials as part of our efforts to play a role in the advancement of medical treatment. This includes treatment trials for breast cancer, liver cancer and head & neck cancer as well as Lymphoma.

Clinical Trials are conducted by doctors who are Good Clinical Practice (GCP) certified. Together with our team of pharmacists, laboratory scientists and nurses, patients are carefully traced throughout the trials conducted.

SHOULD I VOLUNTEER?
HARUSKAH SAYA MENJADI SUKARELAWAN?
我应该成为志愿受试者吗?

Clinical Research Centre, Mahkota Medical Centre is pleased to announce active clinical trials on-going as below :-

No.

Protocol ID

Study Title

Investigator

1.

Z100-01

Randomised, double-blind, placebo-controlled trial of Z-100 Plus Radiation Therapy in patients with Local Advanced Cervical Cancer – A Phase III Trial

English   Bahasa Malaysia   Bahasa Indonesia

Dr Sanjeev Chandra Joshi

2.

B7391003

A Phase 3 randomised, double-blind study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Pacitaxel-Carboplatin for the first-line treatment of patients with advanced non-squamous non-small cell lung cancer

Dr Sanjeev Chandra Joshi

3.

BV-NSCLC-002

A Phase III, open-label, multi-centre, randomised trial to establish safety and efficacy of an EGF cancer vaccine in inoperable, late stage (IIIb/IV) biomarker positive Non Small Cell Lung Carcinoma (NSCLC) patients eligible to receive standard treatment and supportive care

Dr Sanjeev Chandra Joshi

4.

IHN01

Phase III double-blind, placebo-controlled study of post-operative adjuvant concurrent chemoradiotherapy (CTRT) with or without Nimotuzumab for Stage III/IV head and neck squamous cell cancer

Dr Sanjeev Chandra Joshi

 

Trials with patients still ongoing treatment but have stopped recruitment.

No.

Protocol ID

Study Title

Investigator

1.

GP13-301

A randomised, controlled, double-blind Phase III trial to compare the efficacy, safety and pharmacokinetics of GP2013 plus cyclophosphamide, vincristine, prednisone vs. MabThera® plus cyclophosphamide, vincristine, prednisone, followed by GP2013 or MabThera® maintenance therapy in patients with previously untreated, advanced stage follicular lymphoma

Dr Kok
Keng Weng

5.

D4193C00001 (HAWK)

A phase II, multicentre, single-arm, global study of MEDI4736 monotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)

English Bahasa Malaysia 中文

Dr Sanjeev Chandra Joshi

6.

D4193C00003 (CONDOR)

A phase II, randomised, open-label, multicentre, global study of MEDI4736 monotherapy, tremelimumab monotherapy and MEDI4736 in combination with tremelimumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)

English Bahasa Malaysia 中文

Dr Sanjeev Chandra Joshi

 

Trials that have been completed and closed-out.

No.

Protocol ID

Study Title

Investigator

1.

IMCL CP12-0919

A multi-centre, randomised, double-blind, Phase 3 study of Ramucirumab (IMC-1121B) drug product and Best Supportive Care (BSC) versus placebo and BSC as second-line treatment in patients with Hepatocellular Carcinoma following first-line therapy with Sorafenib (REACH)

Dr Jayendran

2.

LA-EP06-302

Pivotal study in breast cancer patients investigating efficacy and safety of LA-EP2006 and Neulasta®

Dr Jayendran

Should you require further information, kindly contact the respective Principal Investigators or Ms Loo Siew Mei at +606-285 2946 / loo.sm@mahkotamedical.com.

 

Operating Hours

8.00am – 5.00pm  (Monday – Friday)

 

Where are we located?

5th Floor, Mahkota Medical Centre

 

Get a Consultation 

Mahkota Medical Centre’s medical team of experienced specialists and officers are trained in different disciplines and are dedicated to caring for your medical needs.

Click here for Consultant Search.

 

Contact Us Now

Telephone :+606-285 2946
Email : loo.sm@mahkotamedical.com